Images List Premium Download Classic

Dyslipidemia

Dyslipidemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor
Regeneron Pharmaceuticals, Inc.
October 12, 2017 - N°20170291937

The present invention provides methods for treating patients suffering from hyperlipidaemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that ...
Growth differentiation factor 15 (gdf-15) polypeptides
Amgen Inc.
October 12, 2017 - N°20170291929

Gdf15 polypeptides, constructs comprising gdf15, and mutants thereof are provided. In various embodiments the gdf15 polypeptides, constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Peptides having reduced toxicity that stimulate cholesterol efflux
The Regents Of The University Of California
October 05, 2017 - N°20170283480

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e. G., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also ...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
Dezima Pharma B.v.
September 21, 2017 - N°20170267640

The present invention relates to a process for the preparation of synthetic intermediates which may be used in the preparation of tetrahydroquinoline derivatives, which derivatives have an inhibitory activity against cholesteryl transfer protein (cetp), show effects of increasing hdl cholesterol level and decreasing ldl cholesterol level, and can be used for the treatment and/or prevention of diseases such as ...
Compositions and methods for diagnosis and treatment of metabolic syndrome
United States Of America, As Represented By The Secretary Of The Navy
September 21, 2017 - N°20170266144

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
Fgf-8 for use in treating diseases or disorders of energy homeostasis
Technische Universität München
September 14, 2017 - N°20170258874

The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis. Also provided by the present invention are pharmaceutical compositions comprising said polypeptides and ...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their ...
Regeneron Pharmaceuticals, Inc.
August 31, 2017 - N°20170246227

The present invention relates to the combination of spirulina and palmitoylethanolamide (pea) and/or pharmaceutically acceptable derivates or salts thereof, pharmaceutical formulations comprising the combination of spirulina and pea and/or pharmaceutically acceptable derivates or salts thereof, optionally together with at least one physiologically acceptable excipient, and the use of the combination of spirulina and pea and/or pharmaceutically acceptable ...
Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
Ionis Pharmaceuticals, Inc.
August 17, 2017 - N°20170233732

Provided herein are methods, compounds, and compositions for reducing expression of apociii mrna and protein in a patient with fredrickson type i dyslipidemia, fcs, lpld. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating fredrickson type i dyslipidemia, fcs, lpld, in a patient. Further provided herein are methods, compounds, and compositions for increasing hdl levels ...
Piperazine derivatives as liver x receptor modulators
Vitae Pharmaceuticals, Inc.
August 10, 2017 - N°20170226067

Provided are novel compounds of formula (i): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver x receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver x receptor. Also provided are the compounds of formula (i) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, alzheimer's disease, dermatitis, dyslipidemia, cancer ...
Methods for reducing ldl-cholesterol
Rinat Neuroscience Corp.
August 10, 2017 - N°20170224816

The present invention relates to methods for the treatment of reducing ldl-cholesterol levels in a subject infected with hepatitis c virus (hcv) or at high risk of contracting hcv comprising administration to the subject in need thereof a therapeutically effective amount of an antagonist antibody which specifically binds to a human pcsk9 protein. The subject treatment can be used in ...
[7,6]-fused bicyclic antidiabetic compounds
Merck Sharp & Dohme Corp.
August 03, 2017 - N°20170217942

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated ...
Antidiabetic bicyclic compounds
Merck Sharp & Dohme Corp.
August 03, 2017 - N°20170217920

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated ...
Antidiabetic bicyclic compounds
Merck Sharp & Dohme Corp.
August 03, 2017 - N°20170217918

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated ...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Materials and methods of treating dyslipidemia
Augusta University Research Institute, Inc.
July 20, 2017 - N°20170202907

Described herein are materials and methods for treating dyslipidemia in a mammalian subject in need thereof comprising administering a growth hormone-releasing hormone (ghrh) antagonist or variant thereof to the subject.
Pcsk9 vaccine and methods of using the same
Stc.unm
July 06, 2017 - N°20170189503

A vaccine construct comprising an antigenic pcsk9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity ...
Consejo Superior De Investigaciones Cientificas
July 06, 2017 - N°20170189456

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products. The invention further relates to the use of a strain of bacteroides uniforms, preferably cect 7771, or of the ...
Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in ...
Consejo Superior De Investigaciones Cientificas
June 29, 2017 - N°20170182048

(hereinafter referred to as compound a) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the ...
Treatment of mixed dyslipidemia
Gemphire Therapeutics, Inc.
June 22, 2017 - N°20170172955

Methods and formulations to reduce elevated levels of lipids and apolipoprotein b in subjects having type iib hyperlipidemia. Methods for preventing, delaying or regressing complications of lipid disorders, including; type iib hyperlipidemia, nafld, and nash. Methods for preventing or delaying primary and secondary cardiovascular events. Kits useful for such methods. Methods for reducing hepatic fibrosis. Methods for reducing plasma fibrinogen ...
Antidiabetic substituted heteroaryl compounds
Merck Sharp & Dohme Corp.
June 15, 2017 - N°20170166578

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula i are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes ...
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
Aveo Pharmaceuticals, Inc.
May 18, 2017 - N°20170137506

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use ...
Pharmaceutical compositions of berberine with epa and dha, and methods thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
May 18, 2017 - N°20170135995

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, ...
Loading